Lindbrook Capital’s Ocular Therapeutix OCUL Stock Holding History

Lindbrook Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$858	Buy	117 +49	+72%	+$377	﹤0.01%	2505
2024 Q4	$581	Hold	68	–	–	﹤0.01%	2584
2024 Q3	$592	Hold	68	–	–	﹤0.01%	2621
2024 Q2	$465	Buy	+68	New	+$420	﹤0.01%	2618
2023 Q3	–	Sell	-401	Closed	-$2.07K	–	2787
2023 Q2	$2.07K	Hold	401	–	–	﹤0.01%	2137
2023 Q1	$2.11K	Buy	+401	New	+$1.9K	﹤0.01%	2223
2022 Q4	–	Sell	-677	Closed	-$3K	–	2953
2022 Q3	$3K	Buy	+677	New	+$3.41K	﹤0.01%	1903
2021 Q4	–	Sell	-5,900	Closed	-$59K	–	2170
2021 Q3	$59K	Sell	5,900 -2,300	-28%	-$25.8K	0.02%	400
2021 Q2	$116K	Buy	8,200 +1,000	+14%	+$15.2K	0.03%	263
2021 Q1	$118K	Buy	7,200 +3,452	+92%	+$66.5K	0.03%	245
2020 Q4	$78K	Buy	3,748 +748	+25%	+$11.1K	0.02%	288
2020 Q3	$23K	Sell	3,000 -2,478	-45%	-$20.6K	0.01%	569
2020 Q2	$46K	Buy	5,478 +4,478	+448%	+$29.7K	0.01%	372
2020 Q1	$5K	Buy	+1,000	New	+$4.94K	﹤0.01%	1006

Other funds holding OCUL

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's OCUL Position: Q1 2025 in Review

Lindbrook Capital increased its Ocular Therapeutix (OCUL) stake by 72% in Q1 2025, buying an estimated $377 and bringing the position to 117 shares worth $858. The position accounts for ﹤0.01% of the portfolio, ranked #2505.

Lindbrook Capital first reported a position in OCUL in Q1 2020 and has held it in 14 quarters since. The position peaked at $118K in Q1 2021. 196 funds tracked by Wall St. Rank hold OCUL as of Q1 2025.

Lindbrook Capital held 117 shares of Ocular Therapeutix worth $858 as of Q1 2025.
Lindbrook Capital bought 49 Ocular Therapeutix shares in Q1 2025, an estimated $377.
Ocular Therapeutix made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2505 holding.
Lindbrook Capital first reported a position in Ocular Therapeutix in Q1 2020 and has held it in 14 quarters since.
Lindbrook Capital's Ocular Therapeutix position peaked at $118K in Q1 2021.
196 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.